Ophthalmology Clinical Trials

Current Clinical Trials

Diabetic Macular Edema

  • DOVETAIL Study—A Multi-center, Non-Randomized, Open-Label, Multiple Ascending Dose Stud to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7200220 in Monotherapy and in Combination with Ranibizumab Following Intravitreal Administration in Patients with Diabetic Macular Edema.

Sponsor: F. Hoffman-La Roche; Principal Investigator: Paul Yates, MD, PhD

  • RHINE Study– A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of RO6867461 in Patients with Diabetic Macular Edema.

Sponsor: Apellis Pharmaceuticals; Principal Investigator: Paul Yates, MD, PhD

Geographic Atrophy

  • DERBY Study—A Phase III, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy with Sham Injections in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD).

Sponsor: Apellis Pharmaceuticals; Principal Investigator: Paul Yates, MD, PhD

  • Re-CLAIM Study—A Phase 2, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects with Age-Related Macular Degeneration with Geographic Atrophy

Sponsor: Stealth BioTherapeutics; Principal Investigator: Yevgeniy Shildkrot, MD

Neovascular Age-Related Macular Degeneration

  • SHORE—A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Ranibizumab, Compared with Ranibizumab Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)

Sponsor: Opthea; Principal Investigator: Michael Cusick, MD

 

For additional information about the trials or to refer a patient, contact the study coordinator:

  • Ashton Leone, MPH at (434) 243-5737 or aml7q@virginia.edu